Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PTGS2 | P35354 | 18/20 | 0.53 |
| ▸ | PTGS1 | P23219 | 14/20 | 0.52 |
| ▸ | ABCB11 | O95342 | 1/20 | 0.48 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.48 |
| ▸ | PDPK1 | O15530 | 1/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL8640455 | 0.95 | PTGS2 (0.45) | PTGS2PTGS1ABCB11ALDH1A1 | |
| SCHEMBL8692192 | 0.88 | PTGS2 (0.42) | PTGS2PTGS1ABCB11ALDH1A1 | |
| SCHEMBL8689604 | 0.87 | PTGS2 (0.41) | PTGS2PTGS1ABCB11ALDH1A1 | |
| SCHEMBL8637024 | 0.87 | PTGS2 (0.54) | PTGS2PTGS1 | |
| Benzenesulfonamide SCHEMBL8525050 | 0.86 | PTGS2 (0.61) | PTGS2PTGS1PDPK1 | |
| Benzenesulfonamide SCHEMBL7046453 | 0.86 | PTGS2 (0.65) | PTGS2PTGS1ABCB11ALDH1A1 | |
| SCHEMBL8639246 | 0.85 | PTGS2 (0.56) | PTGS2PTGS1ALDH1A1 | |
| SCHEMBL7775609 | 0.85 | PTGS2 (0.55) | PTGS2PTGS1ABCB11ALDH1A1 | |
| SCHEMBL8636828 | 0.85 | PDPK1 (0.61) | PTGS2PTGS1ABCB11PDPK1 | |
| SCHEMBL8689324 | 0.84 | PTGS2 (0.45) | PTGS2PTGS1ALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| JP-2001505564-A | — | — | 2001-04-24 | — | — | JP | claimed |
| EP-0941080-A2 | METHOD OF USING CYCLOOXYGENASE-2 INHIBITORS AS ANTI-ANGIOGENIC AGENTS | G.D. SEARLE & CO. (US) | 1999-09-15 | — | — | EP | claimed |
| WO-1998022101-A2 | METHOD OF USING CYCLOOXYGENASE-2 INHIBITORS AS ANTI-ANGIOGENIC AGENTS | G.D. SEARLE & CO. (US) | 1998-05-28 | — | — | WO | claimed |
| EP-1365753-A2 | UROGUANYLIN AND CYCLOOXYGENASE-2 INHIBITOR COMBINATIONS FOR INHIBITION OF INTESTINAL CANCER | Pharmacia Corporation (US) | 2003-12-03 | — | — | EP | disclosed |
| WO-2002062369-A2 | UROGUANYLIN AND CYCLOOXYGENASE-2 INHIBITOR COMBINATIONS FOR INHIBITION OF INTESTINAL CANCER | PHARMACIA CORPORATION (US) | 2002-08-15 | — | — | WO | disclosed |
| EP-0979077-A1 | METHOD OF USING CYCLOOXYGENASE-2 INHIBITORS IN THE PREVENTION OF CARDIOVASCULAR DISORDERS | G.D. Searle & Co. (US) | 2000-02-16 | — | — | EP | disclosed |
| WO-1998047509-A1 | METHOD OF USING CYCLOOXYGENASE-2 INHIBITORS IN THE PREVENTION OF CARDIOVASCULAR DISORDERS | G.D. SEARLE & CO. (US) | 1998-10-29 | — | — | WO | disclosed |